Preformulation and Formulation Investigational New Drugs
Abstract
During the past year (20 months instead of 12 months due to extensions) the following work has been completed: 1. Development of higher dose pyridostigmine bromide extended release tablets at doses of 90, 120, and 150 mg. 2. Formulation and production of a batch (approximately 2200 tablets) of 90 mg extended release pyridostigmine bromide tablets. 3. Characterize the physicochemical properties of aprophen hydrochloride. 4. Formulation and production of 5 mg, 15 mg and placebo WR6026 dihydrochloride capsules in batch sizes of approximately 2500 (5 mg and 15 mg) and approximately 2800 (placebo). 5. Formulation and production of 5 mg, 15 mg and placebo WR238,605 capsules in batch sizes of approximately 3000 (5 mg and 15 mg) and approximately 6000 (placebo).
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 1990
- Accession Number
- ADA252024
Entities
People
- Douglas R. Flanagan
- John L. Lach
- Lloyd E. Matheson Jr.
Organizations
- University of Iowa